Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 4,900 shares, a growth of 19.5% from the February 13th total of 4,100 shares. Currently, 0.3% of the company’s stock are sold short. Based on an average trading volume of 33,200 shares, the days-to-cover ratio is presently 0.1 days.
Galmed Pharmaceuticals Price Performance
Galmed Pharmaceuticals stock traded down $0.12 during trading hours on Thursday, hitting $2.15. The company had a trading volume of 73,356 shares, compared to its average volume of 892,847. Galmed Pharmaceuticals has a fifty-two week low of $1.67 and a fifty-two week high of $23.80. The firm has a market capitalization of $1.38 million, a P/E ratio of -0.13 and a beta of 0.72. The firm’s fifty day moving average is $2.51 and its 200-day moving average is $3.43.
Wall Street Analyst Weigh In
Separately, StockNews.com started coverage on Galmed Pharmaceuticals in a report on Thursday. They issued a “sell” rating on the stock.
Hedge Funds Weigh In On Galmed Pharmaceuticals
An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned about 3.97% of Galmed Pharmaceuticals at the end of the most recent quarter. Institutional investors and hedge funds own 76.14% of the company’s stock.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Further Reading
- Five stocks we like better than Galmed Pharmaceuticals
- Basic Materials Stocks Investing
- 5 Reasons Five Below’s Stock Price Is Heading Higher This Year
- Investing in the High PE Growth Stocks
- Broadcom: Why the Chip Stock Remains a Top Long-Term AI Play
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Defense Stocks Set to Benefit From Increased Military Spending
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
